Wafik S. El-Deiry, MD, PhD, FACP’s Post

Intracelluar oncoproteins like KRAS function as oncodrivers and promote tumor growth by limiting the effectiveness of anti tumor activity of immune CD8+T cells. In vivo, KRASG12D-specific dIgA1, penetrated cancer cells and produced expulsion of oncoproteins and thereby limited the growth of KRASG12D-mutated ovarian and lung carcinomas in a manner dependent on CD8+ T cells. Also in vivo, dIgA specific for IDH1R132H reduced colon cancer growth, demonstrating effective targeting of a cytoplasmic oncodriver not associated with surface receptors. dIgA targeting of KRASG12D restricted tumor growth more effectively than small-molecule KRASG12D inhibitors, supporting the potential of this approach for the treatment of human cancer. #immunotherapy #cancer #dimericiga #kras

The triplet combination of PDS0101, PDS0301, and bintrafusp alfa prolonged survival when used to treat patients with advanced HPV16-positive cancers, according to final survival data from a phase 2 trial. PDS Biotechnology https://lnkd.in/erFS34NC

Novel biomarker for early HCC - schedule a meeting with ImCare at the AASLD- Liver Meeting November 10-14 in Boston   ImCare Biotech has developed a novel technology that is able to detect early-stage liver cancer with significantly higher sensitivity and specificity than AFP, showing a 80% sensitivity and 90% specificity compared to 52% sensitivity and 86% specificity for AFP. The test (Seravue®) has received break through designation from the FDA. The liver-cancer-specific isoform of serine protease inhibitor Kazal (LC-SPIK) has been shown in a study published in Clinical and Translational Gastroenterology as a valuable biomarker for the detection of HCC in patients with chronic liver disease of viral etiology. The biomarker also exhibited considerable performance in early-stage HCC and in patients with false-negative AFP results in a large scale, blinded prospective study. Contact Aaron Lu (yl@imcarebiotech.com) to schedule a meeting to learn more!

With the use of weight loss drugs on the rise, their potential risks and unintended outcomes are still being researched. However, a recent Scandinavian cohort study provides reassuring news regarding GLP1 receptor agonist treatment and thyroid cancer risk. The study found no significant association between the two, offering peace of mind to healthcare providers and patients. While further research is needed to validate these findings and explore long-term effects, this news is a step forward in understanding the safety profile of weight loss drugs. #cancerrisk #weightlossdrugs

Development of a potential microRNA medicine against KRAS mutant cancers https://lnkd.in/ezkGpN7K

The FDA's recent approval of repotrectinib is a game-changer in ROS1 fusion-positive lung cancers. The TRIDENT-1 clinical trial results, published in the New England Journal of Medicine, demonstrate the drug's efficacy in patients who had not previously received a ROS1-targeted drug, with nearly 80% exhibiting a positive response. Repotrectinib's ability to overcome resistance mutations, such as G2032R, provides a viable option for those whose tumors had become resistant to other ROS1 inhibitors. Furthermore, the extended duration of responses, especially in brain metastases, adds to its appeal. Though direct comparisons with other ROS1-targeted drugs and a relatively small participant pool pose limitations, the potential for long-lasting responses and manageable side effects positions repotrectinib as a valuable addition to the treatment armamentarium. As we navigate the evolving landscape of targeted therapies, repotrectinib offers hope and improved outcomes for a subset of patients facing limited treatment choices. The FDA's approval marks a significant milestone in the treatment of advanced lung cancers with ROS1 fusions. #nsclc #lungcancer #fdaapproval #cancertreatment

🔬 Exciting News: Bladder Cancer Diagnosis Breakthrough! 🚀 I'm thrilled to share our latest article, "Exploiting Volatile Fingerprints for Bladder Cancer Diagnosis: A Scoping Review of Metabolomics and Sensor-Based Approaches," which has just been published. 📚 Bladder cancer is a serious health concern, and early detection is crucial. Our comprehensive review delves into innovative metabolomics and sensor-based approaches that promise to revolutionize the diagnosis of this disease.🔍 👉 Dive into the article here: https://lnkd.in/d2eGGf2W I'm immensely proud of our team's dedication to advancing medical research. Let's work together to spread awareness about this critical topic and potentially save lives. #BladderCancer #Metabolomics #EarlyDiagnosis #MedicalResearch #Innovation #Healthcare #Science UCIBIO i4HB Institute for Health and Bioeconomy Toxicology Laboratory

Discover the latest insights from our study exploring the therapeutic potential of IL-37 in combating hepatocellular carcinoma (HCC) in humanized mice! Dive into the details of how IL-37 directly affects HCC growth and the unknown mechanisms underlying its effects. 📄 Journal Article: IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. Highlights: 1.    IL-37 is human-specific and does not have a mouse homolog 2.    Humanized hepatocellular carcinoma (HCC) mouse model was used to investigate the effects of IL-37 3.    Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in the tumour microenvironment by IL-37 promotes glycolysis and oxidative phosphorylation in MDSC. This leads to Adenosine triphosphate (ATP) release which results in enhanced anti-tumour immune responses Humanized mice serve as valuable tools to investigate human-specific markers, run preclinical tests, and develop of novel therapeutics. Read the article here at https://lnkd.in/dUAip25J #Humanizedmice #CancerResearch #Immunotherapy #IL37 #HCC #ScientificBreakthroughs

Credit to Joseph Shavit January 28, 2023 AI-based home saliva test detects cancer with over 90% accuracy https://flip.it/esAreh Based on a technology approved by the US Food and Drug Administration (FDA) as a "breakthrough device," the saliva test can detect early symptoms of oral and throat cancer with more than 90 percent accuracy. Due to a lack of effective diagnostic tools, these cancers often go undiagnosed until they have reached an advanced stage, resulting in low survival rates. In a previous study, Maria Soledad Sosa from the Icahn School of Medicine at Mount Sinai and Julio A. Aguirre-Ghiso, now at Albert Einstein College of Medicine, discovered that the ability of cancer cells to remain dormant is controlled by a protein called NR2F1. “We therefore thought that activating NR2F1 using a small molecule could be an attractive clinical strategy to induce cancer cell dormancy and prevent recurrence and metastasis,” Aguirre-Ghiso explains. In the new JEM study, Sosa and Aguirre-Ghiso’s teams used a computer-based screening approach to identify a drug, named C26, that activates NR2F1. The researchers found that treating patient-derived HNSCC cells with C26 boosted the levels of NR2F1 and arrested cell proliferation. CancerDetect™, produced by Viome Life Sciences, brings unprecedented accuracy to early cancer detection and prevention as the only oral and throat cancer test to offer detection with 95% specificity and 90% sensitivity.

Cancer immunotherapy is moving toward combination regimens with agents of complementary mechanisms of action to achieve more frequent and robust efficacy. Dual combinations also rendered checkpoint inhibitor (CPI)–resistant genetically engineered melanoma model responsive to CPI. Thus, this approach provides a framework for the evaluation of rationally designed combinations in immuno-oncology and yields a promising therapy p/b University of Chicago, Imperial College London, Aslan Mansurov, Trevin Kurtanich, Anna Slezak, Lisa Volpatti, Ph.D., Kevin Chang, Aaron T. Alpar, PhD, Kirsten Refvik, Gustavo Borjas, Ha-Na Shim, Kevin Hultgren, Suzana A Gomes, JUN ISHIHARA, Melody Swartz #immunotherapy #melanoma #translationalmedicine https://lnkd.in/d2Xj6Ey6